Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liver Cancer: What's Close To The Market

Executive Summary

The treatment of liver cancer will have a makeover in coming months, with several products including Bristol’s Opdivo nearing the market for a disease that is often diagnosed late and where previously there have been few meaningful advances in therapy for many years. Two recently published reports from Datamonitor Healthcare have reviewed the disease and the R&D pipeline for the condition.

Advertisement

Related Content

Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown
Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents
Merck & Co. Strengthening Its Strong Position In Immuno-Oncology
Lenvatinib HCC Results Give Sorafenib Cause To REFLECT?
Onxeo Seeks Partner For Its Expanding Oncology Pipeline
Stivarga Filings Reinforce Bayer’s HCC Position, For Now

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099324

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel